NASDAQ:INO Inovio Pharmaceuticals (INO) Stock Forecast, Price & News $0.52 -0.03 (-5.43%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$0.51▼$0.5650-Day Range$0.52▼$0.9452-Week Range$0.51▼$2.82Volume8.97 million shsAverage Volume8.58 million shsMarket Capitalization$137.36 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Inovio Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold1.75 Rating ScoreUpside/Downside282.6% Upside$2.00 Price TargetShort InterestBearish14.94% of Shares Sold ShortDividend StrengthN/ASustainability-0.53Upright™ Environmental ScoreNews Sentiment0.94Based on 2 Articles This WeekInsider TradingSelling Shares$6,708 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.55) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector356th out of 987 stocksSurgical & Medical Instruments Industry35th out of 95 stocks 2.9 Analyst's Opinion Consensus RatingInovio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Inovio Pharmaceuticals has a forecasted upside of 282.6% from its current price of $0.52.Amount of Analyst CoverageInovio Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.94% of the outstanding shares of Inovio Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently decreased by 0.66%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInovio Pharmaceuticals has received a 78.35% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inovio Pharmaceuticals is -0.53. Previous Next 2.2 News and Social Media Coverage News SentimentInovio Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Inovio Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for INO on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat Follows7 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,708.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by Institutions46.44% of the stock of Inovio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inovio Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inovio Pharmaceuticals is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInovio Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inovio Pharmaceuticals (NASDAQ:INO) StockInovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.Read More Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INO Stock News HeadlinesJune 5, 2023 | americanbankingnews.comInovio Pharmaceuticals (NASDAQ:INO) Raised to Hold at StockNews.comMay 25, 2023 | finance.yahoo.comINOVIO to Present at the 2023 Jefferies Healthcare ConferenceJune 10, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 24, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Inovio Pharmaceuticals (INO)May 24, 2023 | finance.yahoo.comINOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock UpMay 24, 2023 | markets.businessinsider.comInovio : EU Grants Orphan Drug Designation For INO-3107May 23, 2023 | finance.yahoo.comINOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionMay 19, 2023 | americanbankingnews.comInovio Pharmaceuticals (NASDAQ:INO) Downgraded by StockNews.com to SellJune 10, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 16, 2023 | marketwatch.com2023-2029 "Needle Free Drug Delivery Devices Market" volume sale, Trends and Market Overview | Report Reviewed by ExpertsMay 16, 2023 | americanbankingnews.comHC Wainwright Comments on Inovio Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:INO)May 15, 2023 | finance.yahoo.comAll You Need to Know About Inovio (INO) Rating Upgrade to BuyMay 15, 2023 | finance.yahoo.comThese Analysts Think Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) Sales Are Under ThreatMay 13, 2023 | finance.yahoo.comAnalysts Have Lowered Expectations For Inovio Pharmaceuticals, Inc. (NASDAQ:INO) After Its Latest ResultsMay 12, 2023 | msn.comRBC Capital Reiterates Inovio Pharmaceuticals (INO) Sector Perform RecommendationMay 12, 2023 | finance.yahoo.comInovio Pharmaceuticals First Quarter 2023 Earnings: Misses ExpectationsMay 11, 2023 | markets.businessinsider.comRBC Capital Keeps Their Hold Rating on Inovio Pharmaceuticals (INO)May 11, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)May 11, 2023 | finance.yahoo.comInovio Pharmaceuticals (INO) Q1 2023 Earnings Call TranscriptMay 10, 2023 | msn.comInovio Pharmaceuticals: Q1 Earnings InsightsMay 10, 2023 | markets.businessinsider.comInovio Pharmaceuticals Inc. Q1 Loss decreases, but misses estimatesMay 10, 2023 | finance.yahoo.comINOVIO Reports First Quarter 2023 Financial Results and Operational HighlightsMay 10, 2023 | msn.comEarnings Scheduled For May 10, 2023May 10, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)May 9, 2023 | americanbankingnews.comInovio Pharmaceuticals (INO) to Release Earnings on WednesdayMay 8, 2023 | finance.yahoo.comNew Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023May 8, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)See More Headlines INO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INO Company Calendar Last Earnings5/10/2023Today6/10/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INO CUSIPN/A CIK1055726 Webwww.inovio.com Phone(267) 440-4200Fax267-440-4242Employees317Year Founded1979Price Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$2.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+282.6%Consensus RatingHold Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-279,820,000.00 Net Margins-2,371.71% Pretax Margin-2,371.71% Return on Equity-97.93% Return on Assets-65.84% Debt Debt-to-Equity RatioN/A Current Ratio4.24 Quick Ratio4.24 Sales & Book Value Annual Sales$10.26 million Price / Sales13.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book0.59Miscellaneous Outstanding Shares262,740,000Free Float257,485,000Market Cap$137.36 million OptionableOptionable Beta1.07 Social Links Key ExecutivesJacqueline E. SheaPresident, Chief Executive Officer & DirectorPeter D. KiesChief Financial OfficerStephen KemmerrerSenior Vice President-Engineering DevelopmentLaurent M. HumeauChief Scientific OfficerJeffrey SkolnikSenior Vice President-Clinical DevelopmentKey CompetitorsCytosorbentsNASDAQ:CTSOBeyond AirNASDAQ:XAIRClearPoint NeuroNASDAQ:CLPTHealth Sciences Acquisitions Co. 2NASDAQ:HSAQKORU Medical SystemsNASDAQ:KRMDView All CompetitorsInsiders & InstitutionsNew York State Common Retirement FundSold 86,300 shares on 5/18/2023Ownership: 0.019%Geode Capital Management LLCBought 286,662 shares on 5/16/2023Ownership: 1.970%Susquehanna International Group LLPSold 157,900 shares on 5/16/2023Ownership: 0.000%Graham Capital Management L.P.Bought 35,380 shares on 5/16/2023Ownership: 0.013%Skaana Management L.P.Sold 4,800 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions INO Stock - Frequently Asked Questions Should I buy or sell Inovio Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares. View INO analyst ratings or view top-rated stocks. What is Inovio Pharmaceuticals' stock price forecast for 2023? 4 Wall Street research analysts have issued 12-month target prices for Inovio Pharmaceuticals' stock. Their INO share price forecasts range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 282.6% from the stock's current price. View analysts price targets for INO or view top-rated stocks among Wall Street analysts. How have INO shares performed in 2023? Inovio Pharmaceuticals' stock was trading at $1.56 at the beginning of the year. Since then, INO stock has decreased by 66.5% and is now trading at $0.5228. View the best growth stocks for 2023 here. When is Inovio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our INO earnings forecast. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its quarterly earnings data on Wednesday, May, 10th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 97.93% and a negative net margin of 2,371.71%. During the same quarter in the prior year, the firm posted ($0.36) earnings per share. What ETFs hold Inovio Pharmaceuticals' stock? ETFs with the largest weight of Inovio Pharmaceuticals (NASDAQ:INO) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI) and WisdomTree BioRevolution Fund (WDNA).Direxion Daily S&P Biotech Bull 3x Shares (LABU). When did Inovio Pharmaceuticals' stock split? Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO? 12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). What is Inovio Pharmaceuticals' stock symbol? Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO." Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (10.62%), BlackRock Inc. (8.93%), Geode Capital Management LLC (1.97%), Bank of America Corp DE (1.35%), Renaissance Technologies LLC (1.01%) and Citigroup Inc. (0.72%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito. View institutional ownership trends. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inovio Pharmaceuticals' stock price today? One share of INO stock can currently be purchased for approximately $0.52. How much money does Inovio Pharmaceuticals make? Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $137.36 million and generates $10.26 million in revenue each year. The biopharmaceutical company earns $-279,820,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. How many employees does Inovio Pharmaceuticals have? The company employs 317 workers across the globe. How can I contact Inovio Pharmaceuticals? Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242. This page (NASDAQ:INO) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.